Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C16orf95 divergent transcript (C16orf95-DT) is a long non-coding RNA mapped to chromosome 16q24.2. As a divergent (antisense) transcript, it is transcribed from the opposite strand near the C16orf95 gene, and is suggested to participate in regulation of gene expression at the transcriptional and epigenetic level, consistent with the general function of divergent lncRNAs. C16orf95-DT is upregulated in several cancers, including bladder cancer and uterine endometrial carcinoma, indicating it may play a role in cancer biology, likely through modulation of chromatin state or recruitment of transcription factors[1][2]. There are no known small-molecule drugs or biologics targeted to this lncRNA, and it is not a direct therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C16orf95 divergent transcript (C16orf95-DT).